• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔伯特·B·萨宾与口服脊髓灰质炎疫苗的研发

Albert B. Sabin and the development of oral poliovaccine.

作者信息

Horaud F

机构信息

Institut Pasteur, Paris, France.

出版信息

Biologicals. 1993 Dec;21(4):311-6. doi: 10.1006/biol.1993.1089.

DOI:10.1006/biol.1993.1089
PMID:8024745
Abstract

There are many reasons for the modern interest in viral vaccines, but there is no doubt that the key role played by viral vaccines in public health is the major factor since other prophylactic or therapeutic anti-viral products simply do not exist. Viral vaccines have a long history that has been marked by successful events and by tragic accidents. Live viral vaccines are an extraordinary category of biologicals since, despite their reputed efficacy, they were developed by empirical experiments and patient epidemiological observation. From this point of view oral polio vaccine should be considered a 'miracle' since it became a major tool for public health in the 20th century, before we were able to understand the molecular basis of polio virus neurovirulence attenuation. The first evidence that polio virus can be attenuated was provided in the early 1940s by Max Theiler, but it was Hilary Koprowsky who demonstrated further in 1952, that a rodent adapted strain was safe and able to immunise a limited number of volunteers. Koprowsky studies were confirmed later during a mass field trial in Africa. However it is undeniable that the patient and systematic work of Albert B. Sabin was primordial in developing live oral attenuated poliovaccine. The excellence of Sabin's testing of poliovirus neurovirulence in the accurate studies that he developed, enabled him to select, after the cloning of viral populations by plaque assay, the best attenuated variants.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

现代社会对病毒疫苗产生兴趣有诸多原因,但毫无疑问,病毒疫苗在公共卫生领域所发挥的关键作用是主要因素,因为其他预防性或治疗性抗病毒产品根本不存在。病毒疫苗有着悠久的历史,既有着成功案例,也发生过悲剧性事故。活病毒疫苗是一类特殊的生物制品,尽管其疗效显著,但它们是通过经验性实验和患者流行病学观察而研发出来的。从这一角度来看,口服脊髓灰质炎疫苗堪称“奇迹”,因为在我们能够理解脊髓灰质炎病毒神经毒性减弱的分子基础之前,它就在20世纪成为了公共卫生的一项主要工具。20世纪40年代初,马克斯·泰勒首次证明脊髓灰质炎病毒可以被减毒,但1952年希拉里·科普罗夫斯基进一步证明,一种适应啮齿动物的毒株是安全的,并且能够使有限数量的志愿者产生免疫。科普罗夫斯基的研究后来在非洲的大规模现场试验中得到了证实。然而,不可否认的是,阿尔伯特·B·萨宾耐心且系统的工作在研发口服减毒活脊髓灰质炎疫苗过程中起到了至关重要的作用。萨宾在其开展的精确研究中对脊髓灰质炎病毒神经毒性进行了出色检测,这使他在通过蚀斑试验克隆病毒群体后,能够挑选出最佳的减毒变异株。(摘要截选至250词)

相似文献

1
Albert B. Sabin and the development of oral poliovaccine.阿尔伯特·B·萨宾与口服脊髓灰质炎疫苗的研发
Biologicals. 1993 Dec;21(4):311-6. doi: 10.1006/biol.1993.1089.
2
An historical outline of the development of live poliovaccine and its non-target effects.脊髓灰质炎活疫苗的发展历史概述及其非靶向效应。
Dev Biol Stand. 1995;84:117-22.
3
Reminiscences of Albert Sabin and his successful strategy for the development of the live oral poliovirus vaccine.阿尔伯特·萨宾的回忆以及他研发口服脊髓灰质炎减毒活疫苗的成功策略。
Proc Assoc Am Physicians. 1996 Mar;108(2):117-26.
4
Albert Sabin and the Coalition to Eliminate Polio from the Americas.阿尔伯特·萨宾与美洲消除脊髓灰质炎联盟。
Am J Public Health. 2009 Jan;99(1):34-44. doi: 10.2105/AJPH.2007.117952. Epub 2008 Nov 13.
5
Albert B. Sabin.阿尔伯特·B·萨宾
Biologicals. 1993 Dec;21(4):297-303.
6
Medicine and the media: polio still paralyses (Albert Sabin, Jonas Salk).医学与媒体:脊髓灰质炎仍会导致瘫痪(阿尔伯特·萨宾、乔纳斯·索尔克)
Br J Hosp Med. 1977 Dec;18(6):595.
7
Infectious cDNA, cell receptors and transgenic mice in the study of Sabin's poliovirus vaccines.
Biologicals. 1993 Dec;21(4):365-9. doi: 10.1006/biol.1993.1097.
8
Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.萨宾单价口服脊髓灰质炎疫苗:既往经验回顾及其在消灭脊髓灰质炎后的潜在用途。
Clin Infect Dis. 2001 Aug 15;33(4):531-41. doi: 10.1086/321905. Epub 2001 Jul 9.
9
[History of development of the live poliomyelitis vaccine from Sabin attenuated strains in 1959 and idea of poliomyelitis eradication].[1959年由萨宾减毒株研制口服脊髓灰质炎活疫苗的发展历程及根除脊髓灰质炎的构想]
Vopr Virusol. 2013 Jan-Feb;58(1):4-10.
10
The history of polio vaccination with "Sabin's OPV" 60 years after its introduction in Italy: an unforgivable "delay".用“沙宾氏减毒口服疫苗”对小儿麻痹症进行免疫接种的历史:引入意大利 60 年后:一个不可原谅的“延误”。
J Prev Med Hyg. 2024 Mar 31;65(1):E105-E112. doi: 10.15167/2421-4248/jpmh2024.65.1.3242. eCollection 2024 Mar.

引用本文的文献

1
Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models.犬、仓鼠和小鼠细胞对具有复制能力的腺病毒11p E1/E3绿色荧光蛋白载体的敏感性对动物疫苗模型的选择具有重要意义。
Front Microbiol. 2021 Oct 27;12:698999. doi: 10.3389/fmicb.2021.698999. eCollection 2021.